Today, as we publish the first note from our CEO, Jan Jensen, you have a chance to see how HD-DoE was built and why it was needed. We hope that you take a closer look at our TrailNotes on our webpage Trailhead Biosystems- which is a forum of perspectives, science, and insights from the Trailhead Team. There will be much more to come, as Developmental Biology, Deep Technology, Cell Therapy, and Future Medicine are subjects worth discussing! And of course, there is also a growing list of iPSC-derived specialized human cells that you should consider using in your research.
Reflections from a founder and inventor - the Trailhead Journey so far. HD-DoE is the basis of Trailhead's ability to control cell fate and phenotype. But it is also much more. Sometimes as a scientist one may witness a technology that is truly changing one's perspective. PCR, DNA arrays, deep sequencing, CRISPR, iPSCs, and now AI/ML are all such technologies. There is a day before, and a day after. For me, HD-DoE has been the most important one, even surpassing the personal impact of PCR as a budding scientist at Novo Nordisk in the early 90'ies. It is the experimentalist's dream. Now, we are looking for partners to make tissues, organs, and curative therapies using our cells, because making the cells is only part of the journey. That is why I have to reflect on the power of the team. Thank you to all the colleagues, friends, officials and investors that have helped get us to this point. https://lnkd.in/exVvrXyz